You're signed outSign in or to get full access.
Director of Healthcare Equity Research at Stifel Financial Corp.
Dylan van Haaften is a Director of Healthcare Equity Research at Stifel Financial Corp., focusing on European medical technology and diagnostics companies such as Smith & Nephew and bioMérieux. He has held this position since 2023, following prior roles within the equity research and healthcare analysis space. Van Haaften’s recent performance includes an average return of -5.5% and a 32.65% success rate on rated stocks, with a track record for publishing price targets and investment recommendations on large-cap healthcare firms. He is based in London, holds professional credentials in securities analysis, and is prominently listed in institutional investor coverage databases.
Dylan van Haaften of Stifel Financial Corp. asked for a clarification on whether the company's tariff guidance assumes the use of the Nairobi Protocol for mitigating duties on products imported into the U.S.
CEO Deepak Nath provided a direct response, stating that the current tariff guidance does not assume the use of the Nairobi Protocol at this time.
Fintool can predict 
SNN's earnings beat/miss a week before the call
Dylan van Haaften of Stifel Financial Corp. asked for clarification on whether the company's tariff guidance assumes the use of the Nairobi protocol for any non-U.S. to U.S. business.
CEO Deepak Nath provided a direct response, stating, 'The short answer is no, not at this time.'
Fintool can write a report on SNN's next earnings in your company's style and formatting
Sought clarification on whether tariff-related measures would be P&L neutral, asked for the customer segment split for LPS equipment, and whether there were concerns about university funding.
The company confirmed that corrective measures for tariffs are intended to be EBITDA-neutral. For LPS instruments, biopharma is the largest segment, followed by academia, with NIH being a low single-digit percentage. No unusual ordering patterns from academia were observed in Q1.
Fintool can predict 
SOAGY's earnings beat/miss a week before the call